Methods of determining patient response by measurement of Her-3
AssigneeLaboratory Corporation of America Holdings
InventorsMichael Bates, Ali Mukherjee, Gordon Parry, Jeff Sperinde, Jennifer W. Cook, Gundo Diedrich, Laurie Goodman, Stephen J. Williams
Life of this patent
Estimating the term…
Abstract
The invention provides methods of measuring and/or quantifying the presence and/or amount of Her-3 and/or Her-3 in a complex in a sample. The invention also provides antibodies specific for Her-3.
Claims51
A method for determining whether a subject with a cancer is likely to respond to treatment with a Her family targeted agent, for predicting a time course of disease during treatment with a Her family targeted agent, and/or for predicting the probability of a significant event in the time course of the subject's cancer during treatment with a Her family targeted agent, comprising:
- (a) obtaining a biological sample from of the subject's cancer;
- (b) measuring the amount of Her-3 in the biological sample using a Her-3 antibody that specifically binds to a polypeptide sequence set forth in one of SEQ ID NOs 1-8;
- (c) determining whether the amount of Her-3 in the subject's sample is above a Her-3 cutoff;
- (d) correlating the amount of Her-3 measured in the biological sample to at least one of determining the relative likelihood of whether a subject with a Her-2 positive cancer will respond to treatment with a Her-family targeted agent, predicting a time course of disease during treatment with a Her family targeted agent, and/or predicting a probability of a significant event in the time course of the subject's cancer during treatment with a Her family targeted agent;
- and
- (e) indicating that the subject is more likely to respond to the Her family targeted agent, more likely to have a long time course during treatment with a Her family targeted agent, and/or less likely to have a significant event during treatment with a Her family targeted agent if the amount of Her-3 in the biological sample is below the Her-3 cutoff as compared to if the Her-3 in the biological sample is above the Her-3 cutoff.
A method for determining whether a subject with a cancer is likely to respond to treatment with a Her family targeted agent, for predicting a time course of disease during treatment with a Her family targeted agent, and/or for predicting the probability of a significant event in the time course of the subject's cancer during treatment with a Her family targeted agent, comprising:
- (a) obtaining a biological sample from the subject's cancer;
- (b) measuring the amount of Her-3 and p95 in the biological sample, wherein the amount of Her-3 antibody that specifically binds to a polypeptide sequence set forth in one of SEQ ID NOs 1-8;
- (c) determining whether the amount of Her-3 in the subject's sample is above a Her-3 cutoff and whether the p95 in the subject's sample is above a p95 cutoff;
- and
- (d) correlating the amount of Her-3 and p95 measured in the biological sample to at least one of determining the relative likelihood of whether a subject with a Her-2 positive cancer will respond to treatment with a Her-family targeted agent, predicting a time course of disease during treatment with a Her family targeted agent, and/or predicting a probability of a significant event in the time course of the subject's cancer during treatment with a Her family targeted agent;
- and
- (e) indicating that the subject is more likely to respond to the Her family targeted agent, more likely to have a long time course during treatment with a Her family targeted agent, and/or less likely to have a significant event during treatment with a Her family targeted agent if the amount of Her-3 in the biological sample is below the Her-3 cutoff than if the Her-3 and/or p95 in the biological sample are above their respective cutoffs.
Dependencies are inferred from the claim text.